Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Current Liabilities (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Total Current Liabilities for 6 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 41.56% year-over-year to $6.8 million, compared with a TTM value of $6.8 million through Sep 2025, down 41.56%, and an annual FY2024 reading of $10.5 million, down 8.29% over the prior year.
  • Total Current Liabilities was $6.8 million for Q3 2025 at Ovid Therapeutics, down from $8.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $16.3 million in Q1 2021 and bottomed at $6.7 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $10.4 million, with a median of $10.1 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities crashed 52.75% in 2022, then surged 64.1% in 2023.
  • Year by year, Total Current Liabilities stood at $14.8 million in 2021, then plummeted by 52.75% to $7.0 million in 2022, then soared by 64.1% to $11.5 million in 2023, then dropped by 8.29% to $10.5 million in 2024, then tumbled by 35.41% to $6.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for OVID at $6.8 million in Q3 2025, $8.9 million in Q2 2025, and $9.3 million in Q1 2025.